Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

The fourth-quarter 2024 earnings cycle is here, with quite a few healthcare companies having reported results. Early reports ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying the clinical development process, will ...

Amgen’s Blincyto (blinatumomab) has been approved by the European Commission (EC) to treat certain acute lymphoblastic ...

The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake ...

We recently compiled a list of the 7 Cheap Quarterly Dividend Stocks to Invest in. In this article, we are going to take a ...

Amgen (NASDAQ:AMGN – Free Report) had its price target decreased by Citigroup from $310.00 to $295.00 in a research report released on Tuesday morning,Benzinga reports. Citigroup currently has a ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.